Literature DB >> 16641673

Expression levels of vascular endothelial growth factor and its receptors in Parkinson's disease.

Keiichirou Wada1, Hiroyuki Arai, Masashi Takanashi, Jiro Fukae, Hideki Oizumi, Toru Yasuda, Yoshikuni Mizuno, Hideki Mochizuki.   

Abstract

Recently, we confirmed the presence of enhanced neural reconstruction in Parkinson's disease and in an animal model of Parkinson's disease based on increased polysialic acid-like immunoreactivity. Changes in neurogenesis often appear parallel to changes in angiogenesis. Moreover, both these processes share similar modulating factors, like vascular endothelial growth factor (VEGF) and its receptors VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1). Using immunohistochemistry, we identified in this study upregulation of VEGF in the substantia nigra but not in the striatum of patients with Parkinson's disease by enzyme-linked immunosorbent assay. Such overexpression may participate in vascular remodeling and neurogenesis in the substantia nigra of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16641673     DOI: 10.1097/01.wnr.0000215769.71657.65

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  32 in total

1.  An angiogenic inhibitor, cyclic RGDfV, attenuates MPTP-induced dopamine neuron toxicity.

Authors:  Aditiben Patel; Giuseppe V Toia; Kalea Colletta; Brinda Desai Bradaric; Paul M Carvey; Bill Hendey
Journal:  Exp Neurol       Date:  2011-06-15       Impact factor: 5.330

2.  Evidence for angiogenesis in Parkinson's disease, incidental Lewy body disease, and progressive supranuclear palsy.

Authors:  Brinda Desai Bradaric; Aditiben Patel; Julie A Schneider; Paul M Carvey; Bill Hendey
Journal:  J Neural Transm (Vienna)       Date:  2011-07-12       Impact factor: 3.575

3.  Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia.

Authors:  K Elisabet Ohlin; Veronica Francardo; Hanna S Lindgren; Stephanie E Sillivan; Sean S O'Sullivan; Andrew S Luksik; Fair M Vassoler; Andrew J Lees; Christine Konradi; M Angela Cenci
Journal:  Brain       Date:  2011-07-19       Impact factor: 13.501

Review 4.  The yin and yang of VEGF and PEDF: multifaceted neurotrophic factors and their potential in the treatment of Parkinson's Disease.

Authors:  Torsten Falk; Robert T Gonzalez; Scott J Sherman
Journal:  Int J Mol Sci       Date:  2010-08-05       Impact factor: 5.923

5.  Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.

Authors:  X Yue; D J Hariri; B Caballero; S Zhang; M J Bartlett; O Kaut; D W Mount; U Wüllner; S J Sherman; T Falk
Journal:  Neuroscience       Date:  2013-11-27       Impact factor: 3.590

Review 6.  Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders.

Authors:  Melanie D Sweeney; Abhay P Sagare; Berislav V Zlokovic
Journal:  Nat Rev Neurol       Date:  2018-01-29       Impact factor: 42.937

Review 7.  Vascular endothelial growth factor: a neurovascular target in neurological diseases.

Authors:  Christian Lange; Erik Storkebaum; Carmen Ruiz de Almodóvar; Mieke Dewerchin; Peter Carmeliet
Journal:  Nat Rev Neurol       Date:  2016-07-01       Impact factor: 42.937

Review 8.  The blood-brain barrier in neurodegenerative disease: a rhetorical perspective.

Authors:  Paul M Carvey; Bill Hendey; Angela J Monahan
Journal:  J Neurochem       Date:  2009-07-31       Impact factor: 5.372

Review 9.  Biphasic mechanisms of neurovascular unit injury and protection in CNS diseases.

Authors:  Takakuni Maki; Kazuhide Hayakawa; Loc-Duyen D Pham; Changhong Xing; Eng H Lo; Ken Arai
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-05-01       Impact factor: 4.388

10.  Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson's disease.

Authors:  Torsten Falk; Shiling Zhang; Scott J Sherman
Journal:  Mol Neurodegener       Date:  2009-12-10       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.